Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Stochastic model of Tsc1 lesions in mouse brain.

Prabhakar S, Goto J, Zhang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO.

PLoS One. 2013 May 16;8(5):e64224. doi: 10.1371/journal.pone.0064224. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/6a5b0a50-27e4-49bc-b82a-9267dd63af53. Zuang, Xuan [corrected to Zhang, Xuan].

2.

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O'Keefe RA, Bordey A.

Int J Dev Neurosci. 2013 Nov;31(7):667-78. doi: 10.1016/j.ijdevneu.2013.02.008. Epub 2013 Feb 26. Review.

3.

Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.

Way SW, McKenna J 3rd, Mietzsch U, Reith RM, Wu HC, Gambello MJ.

Hum Mol Genet. 2009 Apr 1;18(7):1252-65. doi: 10.1093/hmg/ddp025. Epub 2009 Jan 15.

4.

Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology.

Ess KC, Uhlmann EJ, Li W, Li H, Declue JE, Crino PB, Gutmann DH.

Glia. 2004 Apr 1;46(1):28-40.

PMID:
14999811
5.

Brain lesions in tuberous sclerosis complex. Review.

Grajkowska W, Kotulska K, Jurkiewicz E, Matyja E.

Folia Neuropathol. 2010;48(3):139-49. Review.

6.

Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model.

Prabhakar S, Zhang X, Goto J, Han S, Lai C, Bronson R, Sena-Esteves M, Ramesh V, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO.

Neurobiol Dis. 2015 Oct;82:22-31. doi: 10.1016/j.nbd.2015.04.018. Epub 2015 May 24.

7.

Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.

Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke SP, Bajenaru ML, Onda H, Kwiatkowski D, Gutmann DH.

Oncogene. 2002 Jun 6;21(25):4050-9.

8.

Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis.

Kerfoot C, Wienecke R, Menchine M, Emelin J, Maize JC Jr, Welsh CT, Norman MG, DeClue JE, Vinters HV.

Brain Pathol. 1996 Oct;6(4):367-75.

PMID:
8944308
9.

Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

Carson RP, Van Nielen DL, Winzenburger PA, Ess KC.

Neurobiol Dis. 2012 Jan;45(1):369-80. doi: 10.1016/j.nbd.2011.08.024. Epub 2011 Aug 26.

10.

Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis.

Wenzel HJ, Patel LS, Robbins CA, Emmi A, Yeung RS, Schwartzkroin PA.

Acta Neuropathol. 2004 Aug;108(2):97-108. Epub 2004 Jun 5.

PMID:
15185103
11.

Tuberous sclerosis complex and DNA repair.

Habib SL.

Adv Exp Med Biol. 2010;685:84-94. Review.

PMID:
20687497
12.

New developments in the neurobiology of the tuberous sclerosis complex.

Crino PB, Henske EP.

Neurology. 1999 Oct 22;53(7):1384-90. Review.

PMID:
10534239
13.

Evidence for population variation in TSC1 and TSC2 gene expression.

Jentarra GM, Rice SG, Olfers S, Saffen D, Narayanan V.

BMC Med Genet. 2011 Feb 23;12:29. doi: 10.1186/1471-2350-12-29.

14.

Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.

Anderl S, Freeland M, Kwiatkowski DJ, Goto J.

Hum Mol Genet. 2011 Dec 1;20(23):4597-604. doi: 10.1093/hmg/ddr393. Epub 2011 Sep 1.

15.

Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.

Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M.

Hum Mol Genet. 2011 Feb 1;20(3):445-54. doi: 10.1093/hmg/ddq491. Epub 2010 Nov 9.

16.

Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.

Yuan E, Tsai PT, Greene-Colozzi E, Sahin M, Kwiatkowski DJ, Malinowska IA.

Hum Mol Genet. 2012 Oct 1;21(19):4286-300. doi: 10.1093/hmg/dds262. Epub 2012 Jun 29.

17.

Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.

Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA, Vinters HV, Kernie SG, Jensen FE, Sahin M, Kwiatkowski DJ.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):E1070-9. doi: 10.1073/pnas.1106454108. Epub 2011 Oct 24.

18.

A novel mouse model of tuberous sclerosis complex (TSC): eye-specific Tsc1-ablation disrupts visual-pathway development.

Jones I, Hägglund AC, Törnqvist G, Nord C, Ahlgren U, Carlsson L.

Dis Model Mech. 2015 Dec;8(12):1517-29. doi: 10.1242/dmm.021972. Epub 2015 Oct 8.

19.

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.

Magri L, Cominelli M, Cambiaghi M, Cursi M, Leocani L, Minicucci F, Poliani PL, Galli R.

Dis Model Mech. 2013 Sep;6(5):1185-97. doi: 10.1242/dmm.012096. Epub 2013 Jun 5.

20.

Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex.

Boer K, Troost D, Jansen F, Nellist M, van den Ouweland AM, Geurts JJ, Spliet WG, Crino P, Aronica E.

Neuropathology. 2008 Dec;28(6):577-90. doi: 10.1111/j.1440-1789.2008.00920.x. Epub 2008 Apr 11.

PMID:
18410267

Supplemental Content

Support Center